Lupin Launches FDA-Approved Sugammadex Injection in U.S.

Global pharmaceutical company Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection and has launched it in the United States. This injection, bioequivalent to Merck's Bridion®, is indicated for reversing neuromuscular blockade during surgery in adult and pediatric patients aged 2 years and older. The launch introduces a generic alternative, potentially increasing accessibility and affordability for a critical surgical medication.